Table 1.

Population characteristics

ParametersN (%)Median (IQR)
No. of patients95 (100)
Boys50 (53)
Age at diagnosis, yr3.6 (2.5–5.2)
Immunomodulatory  therapy before MMF49 (52)
 Levamisole25 (26)
 Cyclophosphamide21 (22)
 Calcineurin inhibitors20 (21)
No. of relapses between diagnosis and MMF initiation4 (3–6)
Time between diagnosis and MMF initiation, yr2.4 (0.9–5.5)
Follow-up time on MMF, yr2.2 (1.3–3.1)
  • IQR, interquartile range; MMF, mycophenolate mofetil.